Annis Gardner Whiting Capital Advisors’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-7,330
Closed -$744K 1350
2025
Q4
$744K Hold
7,330
0.14% 133
2025
Q3
$401K Buy
+7,330
New +$366K 0.08% 199
2025
Q1
Sell
-12,870
Closed -$723K 773
2024
Q4
$723K Hold
12,870
0.2% 96
2024
Q3
$877K Hold
12,870
0.25% 78
2024
Q2
$544K Buy
12,870
+3,735
+41% +$206K 0.15% 117
2024
Q1
$631K Buy
9,135
+2,195
+32% +$139K 0.23% 86
2023
Q4
$513K Buy
6,940
+1,110
+19% +$72.8K 0.23% 85
2023
Q3
$398K Buy
+5,830
New +$495K 0.21% 91

Other funds holding EXAS

Annis Gardner Whiting Capital Advisors's EXAS Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 7,330 shares — an estimated $744K sold.

Annis Gardner Whiting Capital Advisors first reported a position in EXAS in Q3 2023 and held it in 8 quarters. The position peaked at $877K in Q3 2024. 6 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 7,330 Exact Sciences shares in Q1 2026, an estimated $744K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Exact Sciences in Q3 2023 and held it in 8 quarters.
  • Annis Gardner Whiting Capital Advisors's Exact Sciences position peaked at $877K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.